On Invalid Date, Cytokinetics (NASDAQ: CYTK) reported Q3 2021 earnings per share (EPS) of -$0.95, up 1,800% year over year. Total Cytokinetics earnings for the quarter were -$76.09 million. In the same quarter last year, Cytokinetics's earnings per share (EPS) was -$0.05.
What was CYTK's earnings growth in the past year?
As of Q1 2022, Cytokinetics's earnings has grown null year over year. Cytokinetics's earnings in the past year totalled -$228.67 million.
On Invalid Date, Cytokinetics (NASDAQ: CYTK) reported Q3 2021 revenue of $5.44 million up 86.96% year over year. In the same quarter last year, Cytokinetics's revenue was $41.69 million.
What was CYTK's revenue growth in the past year?
As of Q1 2022, Cytokinetics's revenue has grown -60.33% year over year. This is 1,020.91 percentage points lower than the US Biotechnology industry revenue growth rate of 960.59%. Cytokinetics's revenue in the past year totalled $21.55 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.